XRpro Sciences acquires Icagen assets

XRpro Sciences has acquired the assets of Icagen, a drug firm from parent company Pfizer. XRpro is paying Pfizer $500,000 up front for the Icagen name, technology and employees plus "earn outs" for as much as $10.5 million.